These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8239590)

  • 1. In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.
    Gohara Y; Arai S; Akashi A; Kuwano K; Tseng CC; Matsubara S; Matumoto M; Furudera T
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1826-30. PubMed ID: 8239590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of new quinolones on Mycoplasma pneumoniae-infected hamsters.
    Arai S; Gohara Y; Akashi A; Kuwano K; Nishimoto M; Yano T; Oizumi K; Takeda K; Yamaguchi T
    Antimicrob Agents Chemother; 1993 Feb; 37(2):287-92. PubMed ID: 8383942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.
    Kaku M; Ishida K; Irifune K; Mizukane R; Takemura H; Yoshida R; Tanaka H; Usui T; Tomono K; Suyama N
    Antimicrob Agents Chemother; 1994 Apr; 38(4):738-41. PubMed ID: 8031039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae.
    Ishida K; Kaku M; Irifune K; Mizukane R; Takemura H; Yoshida R; Tanaka H; Usui T; Tomono K; Suyama N
    J Antimicrob Chemother; 1994 Dec; 34(6):875-83. PubMed ID: 7730231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental and clinical studies of sparfloxacin in Mycoplasma pneumoniae infection.
    Kaku M; Ishida K; Kohno S; Koga H; Hara K; Usui T
    Drugs; 1995; 49 Suppl 2():412-3. PubMed ID: 8549381
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.
    Takahata M; Shimakura M; Hori R; Kizawa K; Todo Y; Minami S; Watanabe Y; Narita H
    Antimicrob Agents Chemother; 2001 Jan; 45(1):312-5. PubMed ID: 11120986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae.
    Arai S; Gohara Y; Kuwano K; Kawashima T
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1322-4. PubMed ID: 1416832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro antimicrobial activities of new quinolone antibiotics against Mycoplasma pneumoniae].
    Gohara Y; Arai S; Kuwano K; Kawashima T; Matsu-Ura I
    Nihon Saikingaku Zasshi; 1992 Mar; 47(2):387-93. PubMed ID: 1318981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin.
    Kenny GE; Cartwright FD
    Antimicrob Agents Chemother; 1991 Mar; 35(3):587-9. PubMed ID: 1903913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae.
    Ishida K; Kaku M; Irifune K; Mizukane R; Takemura H; Yoshida R; Tanaka H; Usui T; Suyama N; Tomono K
    Antimicrob Agents Chemother; 1994 Apr; 38(4):790-8. PubMed ID: 8031048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of in-vitro activity of new quinolones, macrolides, and minocycline against Mycoplasma pneumoniae.
    Ikejima H; Yamamoto H; Ishida K; Kaku M; Shimada J
    J Infect Chemother; 2000 Sep; 6(3):148-50. PubMed ID: 11810555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.
    Waites KB; Duffy LB; Schmid T; Crabb D; Pate MS; Cassell GH
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1181-5. PubMed ID: 1929260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.
    Azoulay-Dupuis E; Bedos JP; Vallée E; Hardy DJ; Swanson RN; Pocidalo JJ
    J Infect Dis; 1991 Feb; 163(2):319-24. PubMed ID: 1988515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
    Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1992 Apr; 36(4):856-9. PubMed ID: 1323956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.
    Renaudin H; Bébéar C
    Eur J Clin Microbiol Infect Dis; 1990 Nov; 9(11):838-41. PubMed ID: 1964899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolates.
    Barrett MS; Jones RN
    Diagn Microbiol Infect Dis; 1996 Feb; 24(2):113-6. PubMed ID: 9147907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).
    Kenny GE; Cartwright FD
    Antimicrob Agents Chemother; 1996 Apr; 40(4):1048-9. PubMed ID: 8849228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin.
    Cassell GH; Waites KB; Pate MS; Canupp KC; Duffy LB
    Diagn Microbiol Infect Dis; 1989; 12(5):433-5. PubMed ID: 2515025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent.
    Guinea J; Robert M; Gargallo-Viola D; Xicota MA; Garcia J; Tudela E; Esteve M; Coll R; Pares M; Roser R
    Antimicrob Agents Chemother; 1993 Apr; 37(4):868-74. PubMed ID: 8388202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
    Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
    Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.